Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
• Treatments: Gemcitabine; Oxaliplatin; Rituximab

Criteria

Inclusion Criteria:

1. Age ≥ 18 years.

2. DLBCL and MCL diagnosed patients in primary resistance or relapsed not eligible for intensification chemotherapy followed by Autologous stem cell transplantation (ASCT) for age, comorbidity or previous ASCT.

3. Any IPI or ECOG, capable of understanding the nature of the trial.

4. Writtern Informed Consent.

Exclusion Criteria:

1. Nursing pregnant or lactation period women, or fertile age adults not using effective contraceptive method.

2. CNS lymphoma patients.

3. Patients with severa renal (creatinine> 2,5 UNL) or hepatic (Bilirrubin or ALT/AST> 2,5 UNL) impairement not provided by the same disease

4. HIV positive patients.

5. Serious psychiatric diseases patients that could interfere with their skill to understand the study (including alcoholism or drug addiction).

6. Murine proteins or any other component of the medicines of the study hypersensitivity patients.

7. Patients who have received more than 2 therapeutic previous lines. (for previous ASCT patients, induction and conditioning for the TAPH treatment is considered a single line therapy).